CAS: 54198-88-8; 2-(Chloromethyl)Pyrimidine

相似化合物

936643-80-0 1427454-12-3 126504-85-6

上下游产品

2-methylpyrimidine (5-bromopyrimidine-2-yl)methanol trichlorois°Cyanuric acid 2-(2-propynyloxymethyl)pyrimidine 7-{4-[2-(butoxy)ethoxy]phenyl}-1-isobutyl-N-({4-[(2-pyrimidinyl)methyl]sulfanyl}phenyl)-2,3-dihydro-1H-1-benzazepine-4-carboxamide 2-(pyrimidin-2-yl)acetonitrile triphenyl(pyrimidin-2-ylmethyl)phosphonium chloride

2-甲基嘧啶置于三氯异氰尿酸体系中,用 氯仿 作为反应溶剂,化学反应生成 2-(氯甲基)嘧啶
参考文献:发现功能选择性的7,8,9,10-四氢-7,10-乙醇-1,2,4-三唑并[3,4-A]酞嗪在α3亚基上作为gaba A受体激动剂.
标题:发现功能选择性的7,8,9,10-四氢-7,10-乙醇-1,2,4-三唑并[3,4-A]酞嗪在α3亚基上作为gaba A受体激动剂.
摘要:我们之前已经确定了7,8,9,10-四氢-7,10-乙醇-1,2,4-三唑并[3,4-A]酞嗪(1)是α(3)的有效部分激动剂.受体亚型,对α(1)的结合亲和力具有5倍的选择性.本文描述了在此核心结构的3位和6位上的取代基的详细研究.尽管评估了广泛的组,但相对于alpha(1)亚型,对alpha(3)亚型的亲和力可达到的最大选择性是12倍(对于57).尽管大多数类似物在功效上均未显示选择性,但一些类似物确实在α(1)处表现出部分激动作用,而在α(3)处表现出拮抗作用(例如25和75).但是,测试了两个类似物(93和96),它们都在6位上有三唑取代基,显示出对alpha(3)亚型的疗效明显高于alpha(1)亚型.这是该系列中可以在所需方向上实现选择性的第一个迹象.
DOI:10.1021/jm040883V

专利信息

专利号:US-2021085684-A1
优先权日:2016-07-06
标 题:Pde9 inhibitors for treatment of peripheral diseases
发明人：SVENSTRUP NIELS; PARACHIKOVA ANNA I; MCARTHUR JAMES
权利人:IMARA INC
摘要:The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.

专利号:US-4395551-A
优先权日:1981-12-10
标题:Pyridopyrimidinone compounds
发明人：DEKEYSER MARK A; PIERCE BENJAMIN J; MOORE RICHARD C; HUBBARD WINCHESTER L
权利人:UNIROYAL INC
摘要:A compound of the formula ##STR1## wherein R and R 1 together form a 1,3-butadien-1,4-diyl group optionally substituted with a methyl or chloro group and R 2 is halogen is disclosed. The compound is useful as an intermediate in the synthesis of insecticidal organophosphorus compounds.

专利号:US-11370795-B2
优先权日:2017-05-26
标 题 :Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one

专利号:US-8518944-B2
优先权日:2009-10-28
标 题 :Compounds as casein kinase inhibitors
发明人：SUBRAMANYAM CHAKRAPANI; WAGER TRAVIS T
权利人:SUBRAMANYAM CHAKRAPANI; WAGER TRAVIS T; PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.